MEPOLIZUMAB reduced annual systemic corticosteroid exposure compared with placebo in patients with COPD and type 2 inflammation. In a pooled analysis of three Phase III trials, patients receiving mepolizumab alongside inhaled triple therapy also spent fewer days on high-dose systemic corticosteroids. The reduction in annual exposure was observed at both blood eosinophil thresholds evaluated.
Mepolizumab in COPD Lowers Annual Steroid Exposure
Of the 2,089 patients enrolled across the trials, 1,713 had screening blood eosinophil counts of at least 150 cells/µL, including 1,144 with counts of at least 300 cells/µL. At the 150 cells/µL threshold, mean annual systemic corticosteroid exposure was 434.64 mg with mepolizumab and 609.95 mg with placebo. At the 300 cells/µL threshold, exposure averaged 354.28 mg and 551.52 mg, respectively.
The analysis counted systemic corticosteroid use for any cause and assessed both cumulative exposure and the proportion of days patients received these medications. Days on high-dose systemic corticosteroids were less frequent with mepolizumab than with placebo.
Steroid Exposure During Inhaled Triple Therapy
Researchers pooled data from METREX, METREO, and MATINEE, three randomized, placebo-controlled trials. Eligible patients were at least 40 years old, had been diagnosed with chronic obstructive pulmonary disease (COPD) at least one year earlier, and had a history of exacerbations. All were receiving inhaled triple therapy and had no current asthma diagnosis. Patients received 100 mg of subcutaneous mepolizumab or placebo every four weeks.
Clinical Relevance for Eosinophilic COPD
Systemic corticosteroids are recommended for COPD exacerbations, and repeated courses can add to cumulative exposure. Mepolizumab, a monoclonal antibody that targets interleukin-5, is approved as add-on maintenance therapy for patients with COPD and an eosinophilic phenotype.
For clinicians managing patients with a history of exacerbations on inhaled triple therapy, the analysis provides an estimate of how much systemic corticosteroid exposure may differ when mepolizumab is added. The conference report quantified corticosteroid exposure and time on treatment. Whether the reductions translated into fewer corticosteroid-related complications remains an open question.
Reference
Hanania NA et al. Mepolizumab reduces systemic corticosteroid utilization in COPD with type 2 inflammation: pooled results from phase 3 randomized trials. CHEST Annual Meeting, October 18-21, 2026.